Agilent Technologies (A) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
14 Apr, 2026Executive summary
Q1 FY26 revenue reached $1.80 billion, up 7% reported and 4.4% core year-over-year, with growth across all segments and regions, despite a $10 million weather-related shipping disruption, most of which was recovered in early Q2.
Operating margin was 24.6% (non-GAAP), in line with expectations; GAAP operating margin was 19.6%-19.7%.
Non-GAAP EPS was $1.36, up 4% year-over-year; GAAP EPS was $1.07, down from $1.11.
Growth was driven by strong performance in pharma, chemicals and advanced materials, diagnostics, and innovation launches, with continued market share gains.
The Ignite operating system and procurement savings, pricing realization, and successful M&A integration supported margin expansion and digital order growth.
Financial highlights
Core revenue grew 4.4% year-over-year; reported revenue growth was 7%, with currency providing a 2.6%-3% tailwind.
Gross margin was 52.6%-53.7%, down year-over-year due to tariff headwinds and wage increases.
Operating cash flow was $268 million; $93 million invested in CapEx, $152 million in share repurchases, and $72 million in dividends.
Net leverage ratio ended at 0.8x, maintaining a strong balance sheet.
Cash and cash equivalents at quarter-end were $1.76-$1.758 billion.
Outlook and guidance
FY26 core revenue growth expected at 4%-6%, with reported revenue of $7.3-$7.5 billion and a 1.5% currency tailwind.
FY26 non-GAAP EPS guidance raised to $5.90-$6.04, reflecting 5.5%-8% growth and a $0.04 currency benefit.
Q2 FY26 revenue expected at $1.79-$1.82 billion (4%-5.5% core growth), with non-GAAP EPS of $1.39-$1.42.
Operating margin expansion of 75 bps targeted for the year, with sequential improvement expected as tariff headwinds ease.
FY26 operating cash flow expected at $1.6-$1.7 billion; CapEx: ~$500 million; $290 million in dividends planned.
Latest events from Agilent Technologies
- siRNA manufacturing leadership drives growth in a $4B+ market with expanding capacity and innovation.A
Corporate presentation27 Mar 2026 - Strong growth, innovation, and disciplined strategy support positive outlook for the year.A
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Key votes include director elections, auditor ratification, and Board declassification.A
Proxy Filing6 Feb 2026 - Board seeks approval for director elections, pay, auditor, and Board declassification amid strong governance.A
Proxy Filing6 Feb 2026 - Q2 met expectations, but slower recovery and China headwinds led to a guidance cut.A
Jefferies Global Healthcare Conference31 Jan 2026 - Annual meeting to elect directors, approve pay, ratify auditor, and declassify the Board.A
Proxy Filing23 Jan 2026 - Q3 revenue beat guidance, net income surged, and full-year outlook was raised amid market challenges.A
Q3 202423 Jan 2026 - FY26 targets 4–6% core growth, margin gains, and $7.3B–$7.4B revenue via Ignite and innovation.A
44th Annual J.P. Morgan Healthcare Conference13 Jan 2026 - Q4 non-GAAP EPS up 6% to $1.46; FY25 revenue and EPS growth expected.A
Q4 202412 Jan 2026